58-37-10. Search warrants — Administrative inspection warrants — Inspections and seizures of property without warrant. (1) Search warrants relating to offenses involving controlled substances may be authorized pursuant to the Utah Rules of Criminal Procedure. (2) Issuance and execution of administrative inspection warrants shall be as follows: (a) Any judge or magistrate of this state […]
58-37-11. District court jurisdiction to enjoin violations — Jury trial. (1) The district courts of this state shall have jurisdiction in proceedings in accordance with the rules of those courts to enjoin violations of this act. (2) If an alleged violation of an injunction or restraining order issued under this section occurs, the accused may […]
58-37-12. Enforcement — Coordination and cooperation of federal and state agencies — Powers. The department and all law enforcement agencies charged with enforcing this act shall cooperate with federal and other state agencies in discharging their responsibilities concerning traffic in controlled substances and in suppressing the abuse of controlled substances. To this end, they are […]
58-37-14. Resort for illegal use or possession of controlled substances deemed common nuisance — District court power to suppress and enjoin. (1) Any store, shop, warehouse, dwelling house, building, vehicle, boat, aircraft, or other place to which users or possessors of any controlled substances, listed in schedules I through V, resort or where use or […]
58-37-15. Burden of proof in proceedings on violations — Enforcement officers exempt from liability. (1) It is not necessary for the state to negate any exemption or exception set forth in this act in any complaint, information, indictment or other pleading or trial, hearing, or other proceeding under this act, and the burden of proof […]
58-37-17. Judicial review. (1) Any person aggrieved by a department’s final order may obtain judicial review. (2) Venue for judicial review of informal adjudicative proceedings is in the district court of Salt Lake County. Amended by Chapter 161, 1987 General Session
58-37-18. Prior prosecutions and proceedings continued — Uniform construction. (1) (a) Prosecution for violation of any law or offense occurring prior to the effective date of this act shall not be affected by this act; provided, that sentences imposed after the effective date of this act may not exceed the maximum terms specified and the […]
Effective 5/14/2019 58-37-19. Opiate prescription consultation. (1) As used in this section: (a) “Hospice” means the same as that term is defined in Section 26-21-2. (b) “Initial opiate prescription” means a prescription for an opiate to a patient who: (i) has never previously been issued a prescription for an opiate; or (ii) was previously issued […]
58-37-2.5. Restricted applicability. This chapter does not restrict the sale and use of herbs, herbal products, or food supplements that are not scheduled in this chapter as controlled substances. Amended by Chapter 101, 1990 General Session
Effective 5/5/2021 58-37-22. Electronic prescriptions for controlled substances. (1) Beginning January 1, 2022, each prescription issued for a controlled substance shall be transmitted electronically as an electronic prescription unless the prescription is: (a) for a patient residing in an assisted living facility as that term is defined in Section 26-21-2, a long-term care facility as […]
58-37-3. Controlled substances. (1) All substances listed in Section 58-37-4 or 58-37-4.2 are controlled. (2) All substances listed in the federal Controlled Substances Act, Title II, P.L. 91-513, are controlled. Amended by Chapter 12, 2011 General Session
Effective 7/1/2019 58-37-3.6. Exemption for possession or distribution of a cannabinoid product or expanded cannabinoid product pursuant to an approved study. (1) As used in this section: (a) “Cannabinoid product” means a product intended for human ingestion that: (i) contains an extract or concentrate that is obtained from cannabis; (ii) is prepared in a medicinal […]
Effective 3/17/2021 58-37-3.7. Medical cannabis decriminalization. (1) As used in this section: (a) “Cannabis” means the same as that term is defined in Section 26-61a-102. (b) “Cannabis product” means the same as that term is defined in Section 26-61a-102. (c) “Legal dosage limit” means the same as that term is defined in Section 26-61a-102. (d) […]
Effective 9/23/2019 58-37-3.8. Enforcement. (1) A law enforcement officer, as that term is defined in Section 53-13-103, except for an officially designated drug enforcement task force regarding conduct that is not in accordance with Title 26, Chapter 61a, Utah Medical Cannabis Act, may not expend any state or local resources, including the officer’s time, to: […]
Effective 3/17/2021 58-37-3.9. Exemption for possession or use of cannabis to treat a qualifying illness. (1) As used in this section: (a) “Cannabis” means marijuana. (b) “Cannabis product” means the same as that term is defined in Section 26-61a-102. (c) “Drug paraphernalia” means the same as that term is defined in Section 58-37a-3. (d) “Medical […]
Effective 5/4/2022 58-37-4. Schedules of controlled substances — Schedules I through V — Findings required — Specific substances included in schedules. (1) There are established five schedules of controlled substances known as Schedules I, II, III, IV, and V which consist of substances listed in this section. (2) Schedules I, II, III, IV, and V […]
Effective 5/12/2020 58-37-4.2. Listed controlled substances. The following substances, their analogs, homologs, and synthetic equivalents are listed controlled substances: (1) AB-001; (2) AB-PINACA; N-[1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide; (3) AB-FUBINACA; N-[1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl) methyl]-1H-indazole-3-carboxamide; (4) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide); (5) ADB-CHMINACA (N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1- (cyclohexylmethyl)indazole-3-carboxamide); (6) ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1oxobutan-2-yl)-1- (4-fluorobenzyl)-1H-indazole-3-caboxamide); (7) AKB48; (8) alpha-Pyrrolidinohexanophenone (alpha-PHP) (1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one); (9) alpha-Pyrrolidinovalerophenone (alpha-PVP); (10) AM-694 (1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone); (11) AM-1248; (12) AM-2201 […]
58-37-5.5. Recognized controlled substance analogs. (1) A substance listed under Subsection (2) is an analog, as defined in Subsection 58-37-2(1)(g), if the substance, in any quantity, and in any material, compound, mixture, or preparation, is present in: (a) any product manufactured, distributed, or possessed for the purpose of human consumption; or (b) any product, the […]
Affected by 63I-1-258 on 7/1/2032 Effective 5/4/2022 58-37-6. License to manufacture, produce, distribute, dispense, administer, or conduct research — Issuance by division — Denial, suspension, or revocation — Records required — Prescriptions. (1) (a) The division may adopt rules relating to the licensing and control of the manufacture, distribution, production, prescription, administration, dispensing, conducting of […]
Effective 3/17/2021 58-37-6.5. Continuing education for controlled substance prescribers. (1) For the purposes of this section: (a) “Controlled substance prescriber” means an individual, other than a veterinarian, who: (i) is licensed to prescribe a controlled substance under Title 58, Chapter 37, Utah Controlled Substances Act; and (ii) possesses the authority, in accordance with the individual’s […]
